|Videos|December 22, 2019

Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!

Related Content

Dr. Mariano Provencio says many patients still face recurrence after lung cancer surgery and perioperative treatment aims to improve survival.

Expert Explains Need for Better Outcomes in Resectable Lung Cancer

ByDr. Mariano Provencio

November 7th 2025

Shining a Light on Pancreatic Cancer Progress and Support

ByDr. Suneel Kamath

November 7th 2025

How AI Can Put Patients at the Center of Cancer Care

BySteve Brown ,Lisa Booth

November 6th 2025

Sharing More Than 25 Years of Brain Tumor Survival

ByJeannine Walston

November 6th 2025

Multidisciplinary Care and Unmet Needs for Young Adults With Sarcoma

ByDr. Vinayak Venkataraman

November 6th 2025

Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

Newsletter

Related Content

Expert Explains Need for Better Outcomes in Resectable Lung Cancer

Shining a Light on Pancreatic Cancer Progress and Support

How AI Can Put Patients at the Center of Cancer Care

Sharing More Than 25 Years of Brain Tumor Survival

Multidisciplinary Care and Unmet Needs for Young Adults With Sarcoma

Trending on CURE

Top Blood Cancer Stories from October: Key Updates for Patients

Understanding Your Diagnosis of Bile Duct Cancer

Shining a Spotlight on Pinups4Cancer

Understanding Your Stage 2 Uterine (Endometrial) Cancer

Expert Explains Need for Better Outcomes in Resectable Lung Cancer